ArticleAsian Pacific journal of cancer prevention : APJCP2026
Pattern of Somatic Mutations in the PIK3CA Oncogene and Their Role as a Potential Prognostic Biomarker in Breast Cancer Patients in Sri Lanka: A Pilot Study.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit-alpha (PIK3CA) oncogene is one of the most frequently mutated oncogenes in breast cancer, with mutations influencing prognosis and therapeutic response. This study aimed to determine the pattern of hotspot PIK3CA mutations and assess their association with clinicopathological parameters and relapse-free survival (RFS) among Sri Lankan breast cancer patients. MATERIALS &
methodsA qPCR-based genetic analysis was performed on DNA from formalin-fixed, paraffin-embedded (FFPE) tissue samples of 63 clinically diagnosed female Sri Lankan breast cancer patients, using the QClamp® PIK3CA Mutation Detection Test to detect hotspot mutations in PIK3CA (i.e., H1047R, E545K, E542K), followed by statistical analysis. Patient samples and clinical data were fully anonymized, with no identifying information available to the authors at any point during the study.
resultsSomatic missense PIK3CA mutations H1047R and E542K were detected in 17.46% of the cohort. The E545K mutation was not detected. The observed mutations were associated with an increased risk of lymph node (LN) metastasis (p=0.036, OR 9.60) and reduced recurrence-free survival (RFS) (p<0.001, HR 26.19). Patients with a high Ki67 index (p=0.029, HR 79.69) and LN-positive status (p=0.026, HR 123.94) also showed worse outcomes. In addition, the combination of all three factors- presence of a PIK3CA mutation, LN metastasis, and a high Ki67 index- was associated with reduced RFS (p<0.001).
conclusionDespite being a pilot study, the findings indicate that PIK3CA mutations are associated with adverse prognostic outcomes in Sri Lankan breast cancer patients. These results demonstrate the potential utility of PIK3CA testing and PI3K-targeted therapy in clinical management in Sri Lankan, pending validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.